New company focused on reproductive medicine.

PregLem signed a licensing agreement with Ipsen under which Ipsen will grant PregLem worldwide development and commercialization rights to certain Ipsen compounds, for use in reproductive medicine only.

Sutrepa (an affiliate of Ipsen) has taken a minority equity stake in PregLem and will appoint a representative to its board of directors. PregLem is a biopharmaceutical company specialized in reproductive medicine. It is focused on the development and commercialization of innovative compounds for the treatment of benign gynecological conditions and infertility.

Previous articleEpiVax Receives Federal Grant to Reengineer FVIII Using Immunoinformatics
Next articleMerck to Lead and Fund Advancement of SurModics I-vation Drug Delivery Platform